Review article
https://doi.org/10.26800/LV-144-supl1-2
Genetic variability and COVID-19 disease
Irena Drmić Hofman
; Medicinski fakultet Sveučilišta u Splitu, Katedra za medicinsku kemiju i biokemiju, Split
Snježana Židovec Lepej
; Odjel za imunološku i molekularnu dijagnostiku, Klinika za infektivne bolesti ‘’Dr. Fran Mihaljević’’, Zagreb
Abstract
Numerous studies have described genes and loci associated with severe COVID-19 disease such as those for angiotensin-converting enzyme 2 (ACE2), transmembrane serine protease type 2 (TMPRSS2), tyrosine kinase 2 (TYK2), dipeptidyl peptidase 9 (DPP9), the ABO blood group system, certain alleles and the genes of HLA system encoding immune system receptors. However, it should be noted that a variant in genes encoding molecules important for the biological effect of class I and III interferons, such as the TLR gene, is associated with the highest estimated risk of developing severe critical disease COVID-19, especially in men. The importance of male biological sex as a risk factor for the development of severe COVID-19 disease has been proven by several national and global studies. Recent research has also shown an association between the gene for two enzymes from the uridine diphosphate (UDP) -glucuronosyltransferase family (UGT2A1 and UGT2A2) and the smell and/or taste loss during COVID-19 disease. The aim of this paper is to list out genetic markers for which scientific research has proven biological and clinical significance in SARS-CoV-2 infections, especially in terms of host susceptibility to infection and assessment of disease severity and outcome.
Keywords
COVID-19, SARS-CoV-2, GENETIC VARIABILITY, CLINICAL OUTCOMES
Hrčak ID:
275635
URI
Publication date:
24.4.2022.
Visits: 803 *